NEW YORK (AP) -- OctoPlus N.V. has signed a development and manufacturing contract with drug developer Medicines Co. for an undisclosed amount, the company said Monday.
Under the contract terms, OctoPlus will perform process development and clinical manufacturing for Medicines related to potential heart condition drug MDCO-216.
OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide.
Shares of Medicines, based in Parsippany, N.J., fell 13 cents to $7.83 in morning trading.
